Anti-interleukin-33 antibodies and uses thereof

US11760797B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Gerald R. Nakamura · San Francisco, US
• Dhaya SESHASAYEE · Cupertino, US
• Menno Van Lookeren Campagne · San Francisco, US
• Tiffany WONG · South San Francisco, US
• Jia Wu · Foster City, US
• Hongkang XI · South San Francisco, US
• Jack BEVERS, III · San Mateo, US
• Hiu Nam CHAN · South San Francisco, US
• Laetitia Comps-Agrar · Foster City, US
• Racquel CORPUZ · South San Francisco, US

Key dates

• Filing date: Mar 12, 2021
• Grant date: Sep 19, 2023
• Expiry date: Jun 22, 2041

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).